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INTRODUCTION 
Any pregnancy ending spontaneously prior the fetus can survive is 
defined as miscarriage. Recurrent miscarriage, defined as loss of 3 or more 
consecutive pregnancies affects 1% of couples trying to conceive.  
The important causes for recurrent spontaneous miscarriage includes 
epidemiological factors such as maternal age and numberof previous 
miscarriages, anti-phospholipids syndrome, genetic factors, anatomical 
factors, endocrine factors, immune factors; inherited thrombophilic defects 
etc., 
Autoimmune thyroid disease (AITD) is the most frequent cause of 
Hypothyroidism in women of reproductive age. Thyroid disorders have 
been suspected to cause early pregnancy loss and other adversepregnancy 
outcomes. Although the worst overthypothyroidism is infrequent in 
pregnancy, subclinical hypothyroidism has an incidence of 2-3%. 
Thyroid dysfunction and autoimmunity are relatively common in 
women of reproductive age group and has been associated with various 
adverse pregnancy outcomes such as recurrent miscarriage, preeclampsia 
and preterm labour. The main objective of this study was to find out 
association between anti-Thyroid peroxidase antibody and recurrent 
miscarriages and to evaluate obstetric complications such as preeclampsia 
and preterm labour in them. 
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Maternal age and number of previous miscarriages are two 
independent risk factors for a further miscarriage. Advancing maternal age 
is associated with a decline in both the number and quality of the remaining 
oocytes.  
A large prospective register linkage study reported the age-related 
risk of miscarriage in recognised pregnancies to be: 12–19 years, 13%; 20–
24 years, 11%; 25–29 years, 12%; 30–34 years, 15%; 35–39 years, 25%; 
40–44 years, 51%; and ≥45 years, 93%. 
 Advanced paternal age has also been identified as a risk factor for 
miscarriage. The risk of miscarriage is highest among couples where the 
woman is ≥35 years of age and the man ≥40 years of age. 
Previous reproductive history is an independent predictor of future 
pregnancy outcome. The risk of a further miscarriage increases after each 
successive pregnancy loss, reaching approximately 40% after three 
consecutive pregnancy losses, and the prognosis worsens with increasing 
maternal age. A previous live birth does not preclude a woman developing 
recurrent miscarriage. 
The evidence on the effect of environmental risk factors is based 
mainly on data studying women with sporadic rather than recurrent 
miscarriage. The results are conflicting and biased by difficulties in 
controlling for confounding factors and the inaccuracy of data on exposure 
and the measurement of toxin dose.  
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Maternal cigarette smoking and caffeine consumption have been 
associated with an increased risk of spontaneous miscarriage in a dose-
dependent manner. However, current evidence is insufficient to confirm this 
association. 
Recent retrospective studies have reported that obesity increases the 
risk of both sporadic and recurrent miscarriage 
Definition of Miscarriage and Recurrent Pregnancy Loss 
The term miscarriage (or abortion) is used to describe a pregnancy that 
fails to progress, resulting in death and expulsion of the embryo or fetus. 
The generally accepted definition stipulates that the fetus or embryo should 
weigh 500 g or less, a stage that corresponds to a gestational age of up to 20 
weeks (World Health Organization). 
 Unfortunately, this definition is not used consistently, and pregnancy 
losses at higher gestational ages are also, in some studies, classified as 
miscarriage instead of stillbirth or preterm neonatal death. Thus, from a 
definition perspective, it is important to characterize the population being 
studied so that comparisons across therapeutic trials can be made more 
appropriately and reliably. 
Recurrent miscarriage should, according to the aforementioned 
definition of miscarriage, be defined as at least three consecutive 
miscarriages, whereas recurrent pregnancy loss (RPL) could also include 
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pregnancy losses up to gestational week 28; however, unfortunately there is 
no consensus on the definition of recurrent miscarriage or RPL.Pregnancy 
losses after week 20 are rare, so defining recurrent miscarriage and RPL as 
above will result in almost identical populations. 
In some countries and according to some national guidelines only two 
miscarriages are required for diagnosis of RPL. More and more published 
studies of RPL therefore include women with only two previous 
miscarriages, which from an epidemiological point of view is very 
problematic. 
Chemistry of Thyroid Hormones 
Thyroid hormones are derivatives of the the amino acid tyrosine bound 
covalently to iodine. The two principal thyroid hormones are:  
• thyroxine (also known as T4 or L-3,5,3',5'-tetraiodothyronine) 
• triiodothyronine (T3 or L-3,5,3'-triiodothyronine) 
As shown in the following diagram, the thyroid hormones are basically two 
tyrosines linked together with the critical addition of iodine at three or four 
positions on the aromatic rings. The number and position of the iodines is 
important. Several other iodinated molecules are generated that have little or 
no biological activity; so called "reverse T3" (3,3',5'-T3) is such an example 
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A large majority of the thyroid hormone secreted from the thyroid 
gland is T4, but T3 is the considerably more active hormone. Although 
some T3 is also secreted, the bulk of the T3 is derived by deiodination of T4 
in peripheral tissues, especially liver and kidney. Deiodination of T4 also 
yields reverse T3, a molecule with no known metabolic activity.  
Thyroid hormones are poorly soluble in water, and more than 99% of 
the T3 and T4 circulating in blood is bound to carrier proteins. The principle 
carrier of thyroid hormones is thyroxine-binding globulin, a glycoprotein 
synthesized in the liver. Two other carriers of import are transthyrein and 
albumin. Carrier proteins allow maintenance of a stable pool of thyroid 
hormones from which the active, free hormones are released for uptake by 
target cells.  
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THYROID BIOSYNTHESIS: 
Thyroid hormones are synthesized by mechanisms fundamentally 
different from what is seen in other endocrine systems. Thyroid follicles 
serve as both factory and warehouse for production of thyroid hormones.  
Constructing Thyroid Hormones 
The entire synthetic process occurs in three major steps:  
• Production and accumulation of the raw materials 
• Fabrication or synthesis of the hormones on a backbone or scaffold of 
precursor  
• Release of the free hormones from the scaffold and secretion into blood 
The recipe for making thyroid hormones calls for two principle raw 
materials:  
• Tyrosines are provided from a large glycoprotein scaffold called 
thyroglobulin, which is synthesized by thyroid epithelial cells and secreted 
into the lumen of the follicle - colloid is essentially a pool of thyroglobulin. 
A molecule of thyroglobulin contains 134 tyrosines, although only a 
handful of these are actually used to synthesize T4 and T3. 
• Iodine, or more accurately iodide (I-), is avidly taken up from blood by 
thyroid epithelial cells, which have on their outer plasma membrane a 
sodium-iodide symporter or "iodine trap". Once inside the cell, iodide is 
transported into the lumen of the follicle along with thyroglobulin. 
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Fabrication of thyroid hormones is conducted by the enzyme thyroid 
peroxidase, an integral membrane protein present in the apical (colloid-
facing) plasma membrane of thyroid epithelial cells. Thyroid peroxidase 
catalyzes two sequential reactions:  
1. Iodination of tyrosines on thyroglobulin (also known as "organification of 
iodide"). 
2. Synthesis of thyroxine or triiodothyronine from two iodotyrosines. 
 
 
Through the action of thyroid peroxidase, thyroid hormones accumulate in 
colloid, on the surface of thyroid epithelial cells. Remember that hormone is 
still tied up in molecules of thyroglobulin - the task remaining is to liberate 
it from the scaffold and secrete free hormone into blood.  
Thyroid hormones are excised from their thyroglobulin scaffold by 
digestion in lysosomes of thyroid epithelial cells. This final act in thyroid 
hormone synthesis proceeds in the following steps:  
• Thyroid epithelial cells ingest colloid by endocytosis from their apical 
borders - that colloid contains thyroglobulin decorated with thyroid 
hormone. 
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• Colloid-laden endosomes fuse with lysosomes, which contain hydrolytic 
enzymes that digest thyroglobluin, thereby liberating free thyroid hormones. 
• Finally, free thyroid hormones apparently diffuse out of lysosomes, through 
the basal plasma membrane of the cell, and into blood where they quickly 
bind to carrier proteins for transport to target cells 
 
 
 
 
 
 
 
 
 
 
 
Control of Thyroid Hormone Synthesis and Secretion 
The chief stimulator of thyroid hormone synthesis is thyroid-
stimulating hormone from the anterior pituitary. Binding of TSH to 
receptors on thyroid epithelial cells seems`` Q to enhance all of the 
processes necessary for synthesis of thyroid hormones, including synthesis 
of the iodide transporter, thyroid peroxidase and thyroglobulin.  
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The magnitude of the TSH signal also sets the rate of endocytosis of 
colloid - high concentrations of TSH lead to faster rates of endocytosis, and 
hence, thyroid hormone release into the circulation. Conversely, when TSH 
levels are low, rates of thyroid hormone synthesis and release diminish.  
The thyroid gland is part of the hypothalamic-pituitary-thyroid axis, 
and control of thyroid hormone secretion is exerted by classical negative 
feedback, as depicted in the diagram. Thyroid-releasing hormone (TRH) 
from the hypothalamus stimulates TSH from the pituitary, which stimulates 
thyroid hormone release. As blood concentrations of thyroid hormones 
increase, they inhibit both TSH and TRH, leading to "shutdown" of thyroid 
epithelial cells. Later, when blood levels of thyroid hormone have decayed, 
the negative feedback signal fades, and the system wakes up again.  
A number of other factors have been shown to influence thyroid hormone 
secretion. In rodents and young children, exposure to a cold environment 
triggers TRH secretion, leading to enhanced thyroid hormone release. This 
makes sense considering the known ability of thyroid hormones to spark 
body heat production   
MATERNAL THYROID FUNCTION DURING PREGNANCY 
Normal pregnancy entails substantial changes in thyroid function in 
all animals. These phenomena have been studied most extensively in 
humans, but probably are similar in all mammals. Major alterations in the 
thyroid system during pregnancy include:  
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• Increased blood concentrations of T4-binding globulin: TBG is one of 
several proteins that transport thyroid hormones in blood, and has the 
highest affinity for T4 (thyroxine) of the group. Estrogens stimulate 
expression of TBG in liver, and the normal rise in estrogen during 
pregnancy induces roughly a doubling in serum TBG concentrations. 
• Increased levels of TBG lead to lowered free T4 concentrations, which 
results in elevated TSH secretion by the pituitary and, consequently, 
enhanced production and secretion of thyroid hormones. The net effect of 
elevated TBG synthesis is to force a new equilibrium between free and 
bound thyroid hormones and thus a significant increase in total T4 and T3 
levels. The increased demand for thyroid hormones is reached by about 20 
weeks of gestation and persists until term. 
• Increased demand for iodine: This results from a significant pregnancy-
associated increase in iodide clearance by the kidney (due to increased 
glomerular filtration rate), and siphoning of maternal iodide by the fetus. 
The World Health Organization recommends increasing iodine intake from 
the standard 100 to 150 ug/day to at least 200 ug/day during pregnancy. 
• Thyroid stimulation by chorionic gonadotropin: The placenta of humans 
and other primates secrete huge amounts of a hormone called chorionic 
gonadotropin (in the case of humans, human chorionic gonadotropin or 
hCG) which is very closely related to luteinizing hormone. TSH and hCG 
are similar enough that hCG can bind and transduce signalling from the 
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TSH receptor on thyroid epithelial cells. Toward the end of the first 
trimester of pregnancy in humans, when hCG levels are highest, a 
significant fraction of the thyroid-stimulating activity is from hCG. During 
this time, blood levels of TSH often are suppressed, as depicted in the figure 
to the right. The thyroid-stimulating activity of hCG actually causes some 
women to develop transient hyperthyroidism. 
The net effect of pregnancy is an increased demand on the thyroid 
gland. In the normal individuals, this does not appear to represent much of a 
load to the thyroid gland, but in females with subclinical hypothyroidism, 
the extra demands of pregnancy can precipitate clinicial disease.  
Thyroid Hormones and Fetal Brain Development 
In 1888 the Clinical Society of London issued a report underlining 
the importance of normal thyroid function on development of the brain. 
Since that time, numerous studies with rats, sheep and humans have 
reinforced this concept, usually by study of the effects of fetal and/or 
maternal thyroid deficiency. Thyroid hormones appear to have their most 
profound effects on the terminal stages of brain differentiation, including 
synaptogenesis, growth of dendrites and axons, myelination and neuronal 
migration.  
Thyroid hormones act by binding to nuclear receptors and modulating 
transcription of responsive genes. Thyroid hormone receptors are widely 
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distributed in the fetal brain, and present prior to the time the fetus is able to 
synthesize thyroid hormones.  
It has proven surprisingly difficult to identify the molecular targets 
for thyroid hormone action in the developing brain, but some progress has 
been made. For example, the promoter of the myelin basic protein gene is 
directly responsive to thyroid hormones and contains the expected hormone 
response element. This fits with the observation that induced 
hypothyroidism in rats leads to diminished synthesis of mRNAs for several 
myelin-associated proteins.  
It seems clear that there is a great deal more to learn about the molecular 
mechanisms by which thyroid hormones support normal development of the 
brain.  
Thyroid Deficiency in the Fetus and Neonate 
The fetus has two potential sources of thyroid hormones - it's own 
thyroid and the thyroid of it's mother. Human fetuses acquire the ability to 
synthesize thyroid hormones at roughly 12 weeks of gestation, and fetuses 
from other species at developmentally similar times. Current evidence from 
several species indicates that there is substantial transfer of maternal thyroid 
hormones across the placenta. Additionally, the placenta contains 
deiodinases that can convert T4 to T3.   
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The major thyroid hormone secreted by the fetus is T4. However, 
total T3 and free T3 levels are low throughout gestation, and levels of RT3 
are elevated, paralleling the rise in T4.  Like T3, this compound is derived 
predominantly from conversion of T4 in peripheral tissues. 
The increased production of T4 in fetal life is compensated by rapid 
conversion to the inactive RT3, allowing the fetus to conserve its fuel 
resources. However, there is some evidence that RT3, as well as T4, 
through nongenomic actions, regulate fetal brain development. 
The fetus is iodine deficient when a mother’s iodine intake is low. 
Supplying the mother adequate iodine is an important problem in many 
parts of the world. A fetalgoiter is occasionally detected by ultrasonography 
at a size that could impede normal delivery. The fetus can be treated, with 
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regression of the goiter, by the administration of levothyroxine into the 
amniotic fluid. 
 However, the fetus is usually protected by the transplacental transfer 
of maternal T4, and, therefore, fetal treatment of hypothyroidism can 
usually be postponed until delivery. 
There are three types or combinations of thyroid deficiency states 
known to impact fetal development:  
Isolated maternal hypothyroidism: 
Overt maternal hypothyroidism typically is not a significant cause of 
fetal disease because it usually is associated with infertility. When 
pregnancy does occur, there is increased risk of intrauterine fetal death and 
gestational hypertension. Subclincial hypothyroidism is increasingly being 
recognized as a cause of developmental disease - this is a rather scary 
situation.  
Several investigators have found that mild maternal hypothyroidism, 
diagnosed only retrospectively from banked serum, may adversely affect the 
fetus, leading in children to such effects as slightly lower performance on 
IQ tests and difficulties with schoolwork. The most common cause of 
subclinical hypothyroidism is autoimmune disease, and it is known that 
anti-thyroid antibodies cross the human placenta. Thus, the cause of this 
disorder may be a passive immune attack on the fetal thyroid gland. 
Isolated fetal hypothyroidism: 
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This condition is also known as sporadic congenital hypothyroidism. 
It is due to failure of the fetal thyroid gland to produce adequate amounts of 
thyroid hormone. Most children with this disorder are normal at birth, 
because maternal thyroid hormones are transported across the placenta 
during gestation. What is absolutely critical is to identify and treat this 
condition very shortly after birth. If treatment is not instituted quickly, the 
child will become permanently mentally and growth retarded - a disorder 
called cretinism. This problem has largely due to large scale screening 
programs to detect hypothyroid infants. 
Iodine deficiency - Combined maternal and fetal hypothyroidism: Iodine 
deficiency is, by a large margin, the most common preventable cause of 
mental retardation in the world. Without adequate maternal iodine intake, 
both the fetus and mother are hypothyroid, and if supplemental iodine is not 
provided, the child may well develop cretinism, with mental retardation, 
deaf-mutism and spasticity.  
The World Health Organization estimated in 1990 that 20 million 
people had some degree of brain damage due to iodine deficiency 
experienced in fetal life. Endemic iodine deficiency remains a substantial 
public health problem in many parts of the world, including many areas in 
Europe, Asia, Africa and South America.  
In areas of severe deficiency, a large fraction of the adult population 
may show goiters. In such settings, overt cretinism may occur in 5 to 10 
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percent of offspring, and perhaps five times that many children will have 
mild mental retardation. This is a serious, tragic and, most importantly, a 
preventable problem. 
The effects of mild maternal hypothyroidism on cognitive function of 
children has been evaluated in several studies, including some in which 
mothers will low levels of T4 or high levels of TSH were treated 
prophylactically with thyroid supplementation. The results of these studies 
are somewhat divergent, and the benefit of routinely testing pregnant 
women and treating those with suspected thyroid deficiency remains 
unsettled. 
The fetus of an iodine-deficient mother can be successfully treated if 
iodine supplementation is given during the first or second trimester. 
Treatment during the third trimester or after birth will not prevent the 
mental defects.  
Iodine deficiency can also be a sigificant problem in animal 
populations. The most common manifestation in sheep, cattle, pigs and 
horses is a high incidence of stillbirths and birth of small, weak offspring.  
 
Hyperthyroidism in Pregnancy 
Gestational hyperthyroidism is associated with increased risk of 
several adverse outcomes, including preeclampisa, premature labor, fetal or 
perinatal death and low birth weight. In humans, hyperthyroidism usually is 
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the result of Grave's disease, which involves development of autoantibodies 
against the TSH receptor that stimulate the thyroid gland. 
MATERNAL AND FETAL THYROID LEVELS : 
In response to the metabolic demands of pregnancy, there is an 
increase in the basal metabolic rate (which is mainly due to fetal 
metabolism), iodine uptake, and the size of the thyroid gland caused by 
hyperplasia and increased vascularity. However, despite this increase in 
thyroid activity, a pregnant woman is euthyroid with levels of TSH, free T4, 
and free T3 remaining within the normal range; thyroid nodules and goiter 
require evaluation.  
During pregnancy, iodide clearance by the kidney increases. For this 
reason (plus the iodide losses to the fetus), the prevalence of goiter is 
increased in areas of iodine deficiency. In many parts of the world, iodine is 
not sufficiently available in the environment, and pregnancy increases the 
risk of iodine  deficiency. 
The increase in thyroid activity in pregnancy is accompanied by a 
marked increase in the circulating levels of TBG in response to estrogen; 
therefore, a new equilibrium is reached with an increase in the bound 
portion of the thyroid hormone. The mechanism for the estrogen effect on 
TBG is an increase in hepatic synthesis and an increase in glycosylation of 
the TBG molecule that leads to decreased clearance. 
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The increase in thyroid activity is attributed to the thyrotropic 
substances secreted by the placenta: a chorionic thyrotropin and the 
thyrotropic activity in human chorionic gonadotropin (hCG). 
 It has been calculated that hCG contains approximately 1/4,000th of 
the thyrotropic activity of human TSH. In conditions with very elevated 
HCG levels, the thyrotropic activity can be sufficient to produce 
hyperthyroidism (gestational hyperthyroidism), and this can even be 
encountered in normal pregnancy TBG levels reach a peak (twice 
nonpregnant levels) at about 15 weeks, which is maintained throughout the 
rest of pregnancy. 
T4 undergoes a small increase in the first trimester, but T3 increases 
more markedly. Because of the increase in TBG, free T4 and T3 levels then 
decrease, although they remain within the normal range. There is an inverse 
relationship between maternal circulation levels of TSH and hCG.60 TSH 
reaches a nadir atthe same time that hCG reaches a peak at 10 weeks of 
pregnancy. TSH levels then increase as hCG levels drop to their stable 
levels throughout the rest of pregnancy.  
Thus, the range of normal for TSH levels change with each 
trimester. The lower limit of TSH in the first and second trimesters is 0.03 
and 0.13 mU/L in the third trimester. The upper limit of normal in the 
first trimester is 2.3 and 3.5 mU/L in the second and third trimesters. 
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These changes support a role for hCG stimulation of the maternal 
thyroid gland, especially during early pregnancy, providing a small but 
important increase in maternal thyroid hormones for the fetus until fetal 
thyroid function is sufficient to serve fetal needs. 
 It is well recognized that patients who have conditions associated 
with very high levels of hCG (trophoblastic disease, hCG-secreting cancers) 
can develop hyperthyroidism. The thyroid stimulating activity of hCG is 
explained by the molecular homology between hCG and TSH, and between 
their receptors. 
In normal pregnancies, placental transfer of TSH, T4, and T3 is 
limited in both directions. Slight, but significant, transfer of T4 and T3 does 
occur, however, when maternal levels are very high or when fetal levels are 
substantially lower than the maternal levels.  
Therefore, in the early weeks of pregnancy, before the fetal thyroid 
gland becomes active, the fetal brain is dependent on the placental transport 
of maternal T4. Both overt and subclinical maternal hypothyroidism are 
associated with increased risks of miscarriage, preeclampsia, low birth 
weight, premature delivery, and a decrease in intelligence in the children. 
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Epidemiological Parameters Relevant for Recurrent Pregnancy Loss 
Occurrence 
Using the traditional definition, the incidence of RPL is the number 
of new women each year (or in another defined period) suffering their third 
consecutive pregnancy loss, and the prevalence of RPL is the number of 
women in a population who, at a specific time point, have had three or more 
consecutive pregnancy losses. The incidence/prevalence is often expressed 
as a rate of those individuals being at risk for the disorder.  
The number in the denominator could be all women in the population, 
women of fertile age or women who had attempted pregnancy at least two 
or three times. Indeed, the estimateof the incidence/prevalence of RPL is 
very uncertain since in most countries there is no nationwide registration of 
miscarriages or RPL, and many early miscarriages will not be treated in 
hospitals and are thus not registered.  
There is no valid estimate of the incidence of RPL whereas there are 
a few estimates of the prevalence rate of RPL. One of the most informative 
studies of the prevalence rate of RPL was performed by Alberman,who 
asked female doctors to report retrospectively about the outcome of their 
previous pregnancies. 
 Nine out of 742 + 355 women (0.8%) who had had three or four 
previous pregnancies reported three or more consecutive pregnancy losses. 
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This study must still be considered the best estimate of the prevalence of 
RPL since the cohort was restricted to women who had attempted 
pregnancy at least three times, and because it consisted of doctors it is 
expected that misclassification of delayed menstruations, induced abortions, 
and ectopic pregnancies as miscarriages will be small. 
However, since the study is from before 1980 many early 
miscarriages may not have been registered due to lack of highly sensitive 
human chorionic gonadotropin tests and ultrasound examinations at that 
time. Furthermore, female doctors may not reflect the background 
population: on one side they may be healthier than other women, which 
may lower the miscarriage risk, but on the other side, due to their long 
education they are older than average when attempting pregnancy, which 
increases the miscarriage risk. 
Other estimates of the population prevalence of RPL are roughly in 
accordance with that of Alberman. An RPL prevalence of 2.3% was found 
in 432 randomly identified women in a multicenter study.4 In a group of 
5901 Norwegian women with at least two pregnancies screened for 
toxoplasma antibodies, 1.4% had experienced RPL.5 Data from a Danish 
questionnaire-based study6 found, in a random sample of 493 women with 
at least two intrauterine pregnancies, that 0.6% had had at least three 
consecutive miscarriages, 0.8% at least three consecutive pregnancy losses 
during all trimesters, and 1.8% had had at least three, not necessarily 
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consecutive, losses some time during pregnancy. Overall, these studies thus 
find the prevalence of RPL to be between 0.6% and 2.3%. 
Number of Previous Miscarriages 
Almost all prospective studies of RPL patients show remarkable 
consistency in finding an increasing risk of miscarriage as the number of 
previous miscarriages increases. The chance of subsequent live birth in 
untreated RPL patients with three, four, and five or more miscarriages has 
been found to be 42–86%, 41–72%, and 23–51%, respectively.The 
significant variability in the estimate of the subsequent risk of miscarriage 
in RPL patients can probably be attributed to the time of ascertainment of 
the pregnancies since the average age of the patients and the duration of 
follow-up in the various studies were not different.  
Thyroid Abnormalities and Pregnancy Loss 
Hyperthyroidism 
Hyperthyroidism occurs in approximately 0.1–0.4% of pregnancies.It 
seems that excess production of thyroid hormone usually is not correlated 
with infertility or RPL. Women with subclinical or mild hyperthyroidism 
have evidence of ovulation when endometrial sampling is performed. 
Pregnant women with untreated overt hyperthyroidism are at increased risk 
for spontaneous miscarriage, congestive heart failure, thyroid storm, 
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preterm birth, pre-eclampsia, fetal growth restriction, and increased 
perinatal morbidity and mortality. 
Treatment of overt Graves’ hyperthyroidism in pregnancy to achieve 
adequate metabolic control has been associated with improved pregnancy 
outcomes.However, hyperthyroidism has not been reported commonly as an 
independent cause of RPL. Only a recent retrospective study has suggested 
that excess exogenous thyroid hormone is associated with an elevated rate 
of fetal loss. 
A study by Nakayama et al.study was performed in a unique 
population of patients with a genotype (Arg243-Gln mutation in the TH 
receptor β gene) showing resistance to thyroid hormone, and a high serum 
concentration of free thyroxine (FT4) and tri-iodothyronine without 
suppressed thyrotropin. These women maintain a euthyroid state despite 
high thyroid hormone levels. Patients were analyzed in three different 
groups: affected mothers (n = 9), affected fathers (n = 9), and unaffected 
relatives (n = 18). 
 The mean miscarriage rates were 22.9, 2.0, and 4.4%, respectively 
(χ2 = 8.66; p = 0.01). Affected mothers had an increased rate of miscarriage 
(z = 3.10; p = 0.002, by Wilcoxon rank-sum test). 
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Hypothyroidism 
The most common cause of hypothyroidism in pregnant women, 
affecting approximately 0.5% of patients is chronic autoimmune thyroiditis 
(Hashimoto’s thyroiditis).Other causes of hypothyroidism include endemic 
iodine deficiency (ID), prior radioactive iodine therapy and thyroidectomy. 
There seems to be no doubt that hypothyroidism is associated with 
infertility. 
Untreated hypothyroidism in pregnancy has consistently been shown 
to be associated with an increased risk for adverse pregnancy complications, 
as well as detrimental effects on fetal neurocognitive development.30 
Specific adverse outcomes associated with maternal overt hypothyroidism 
include increased risks for premature birth, low birth weight, and 
miscarriage 
Thyroid hormones have an impact on oocytes at the level of the 
granulosa and luteal cells that interfere with normal ovulation.Low 
thyroxine levels have a positive feedback on thyroid-releasinghormone 
(TRH). Elevations in TRH have been associated with PRL elevation.It is 
believed that elevated PRL alters the pulsatility of gonadotropin-releasing 
hormone (GnRH) and interferes with normal ovulation. 
Therefore, severe forms of hypothyroidism rarely complicate 
pregnancy because they are associated with anovulation and infertility. 
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Even if an association exists between low thyroid function and pregnancy 
loss, direct evidence for a causal role is missing.One postulated explanation 
for this relationship is that LPD has been linked to thyroid hypofunction.  
A study of thyroid function and pregnancy outcome in 2009 
demonstrated a positive linear relationship between fetal loss and maternal 
thyroid-stimulating hormone (TSH) levels assayed in healthy women, 
without overt thyroid dysfunction.Surprisingly, in this study any association 
was found between FT4 levels and subsequent risk of child loss in these 
women. 
We believe it is prudent to screen for thyroid disease and normalize 
thyroid function prior to conception when function is found to be abnormal. 
Even if there is no clear cause–effect relationship between hypothyroidism 
and RPL, there is some evidence that subclinical hypothyroidism is 
correlated with poor maternal outcome as well as prematurity and reduced 
intelligence quotient in the offspring. 
There is disagreement as to the suitable upper limit of normal serum 
TSH in order to make the diagnosis of subclinical hypothyroidism. There is 
a trend with the new TSH assays to decrease the upper limit of normal TSH 
(range, 4.5 to 5.0 mU/L) to 2.5 mU/L. This upper limit is recommended by 
the National Academy of Clinical Biochemistry guideline, and based on the 
fact that 2.5 mU/L represents more than 2 standard deviations above 
meticulously screened euthyroid volunteers.Clearly, this new upper limit 
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will significantly increase the number of patients diagnosed with subclinical 
hypothyroidism, and its clinical benefit remains questionable. 
 
Thyroid peroxidase antibody 
Thyroid peroxidase is a poorly glycosylated membrane-bound 
enzyme, responsible for iodine  oxidation and iodination of thyrosyl 
residues of the Tg molecule ` It had been termed microsomal antigen based 
on its intracellular localization. Antibodies react against conformational 
epitopes at the surface of the molecules and against linear epitopes . 
Polyclonal antibodies from healthy individuals and patients are directed 
against the same epitopes. 
 Anti-TPO antibodies from healthy subjects did not block TPO 
activity or interfere with the blocking activity of anti-TPO antibodies from 
AITD patients , while anti-TPO antibodies from AITD patients can fix 
complement, destroy thyrocytes, and act as competitive inhibitors of 
enzymatic activity . These antibodies can be of any class of IgG, although 
some studies indicated a higher prevalence of IgG1 (70%) and IgG4 
(66.1%) compared to IgG2 (35.1%) and IgG3 (19.6%). 
 Low levels of IgA antibodies have also been reported . Anti-TPO 
antibodies are more common than anti-Tg antibodies and more indicative 
for thyroid disease. Anti-TPO antibodies are inductors of oxidative stress 
evidenced by decreased antioxidant potential, advanced glycosylation 
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products and oxygen metabolites in blood . However, their contribution to 
thyroid damage compared to T cell and cytokine-mediated apoptosis is 
minor . Anti-TPO antibodies are detected in 90–95% of AITD patients, 80% 
of GD, and 10–15% of non-AITD patients. 
 While anti-TPO antibodies may act cytotoxic on thyrocytes in HT 
they do not have an established role in GD. Anti-TPO antibodies are able to 
cross the placenta barrier to variable extent, but the effect on the neonate is 
unclear. Concerns on a potential negative effect on cognitive development 
of the offspring have not been confirmed so far. 
Symptoms can be mild, and patients might not seek medical advice. Even 
when treatment has been initiated, titers of anti-TPO antibodies decrease 
only slowly (e.g., over 5 years) upon treatment with levothyroxine, and anti-
TPO antibody titers remain in the pathological range. Normal anti-thyroid 
antibody titers are lower for anti-TSHR antibodies than for anti-TPO and 
anti-Tg antibodies. 
Thyroid Autoimmunity and Pregnancy Loss 
Autoimmune thyroid disease is the most common endocrine disorder 
in women of reproductive age with an overall prevalence in women of 10 to 
15%38 and among pregnant women, autoimmune thyroid disease has a 
prevalence of 5 to 20%.39 In recent years many studies have found an 
association between thyroid autoimmunity (TA) and recurrent abortions; 
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moreover it has been suggested that thyroid autoantibodies may be 
employed as a marker for at-risk pregnancies. 
Many studies have linked TA with recurrent miscarriages, although 
the mechanism involved is unclear. Despite this, three mechanisms have 
been postulated to explain the possible association between TA and early 
pregnancy loss:  
(1) the presence of thyroid autoantibodies reflects a generalized activation 
of the immune system and a generally heightened autoimmune reactivity 
against the feto-placental unit 
(2) The presence of thyroid autoantibodies may act as an infertility factor 
and may delay conception. Thus, when women with thyroid autoantibodies 
do become pregnant, they are older and have a higher risk of miscarriage 
(3) The presence of thyroid autoantibodies in euthyroid women may be 
linked with a mild deficiency in thyroid hormone concentrations or a lower 
capacity of the thyroid gland to adapt to the demands of the pregnancy state.  
Indeed, the mean serum TSH values, while being within normal 
range, were significantly higher in thyroid autoantibody positive women 
compared to women with negative thyroid autoantibodies. This may reflect 
lower thyroidal reserve during pregnancy when a greater amount of thyroid 
hormones is demanded.However, the various hypotheses mentioned above 
are not contradictory to each other, so it is possible that the mechanisms 
explained act in concert. 
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Thyroxine administration seems to be effective in reducing the 
number of miscarriages when given during the early stages of pregnancy, 
because miscarriages with maternal thyroid autoimmunity generally occur 
within the first trimester.Poppe et al. have proposed that serum TSH, free 
FT4 and thyroid autoantibodies should be measured in early gestation. 
When serum TSH is elevated or free FT4 is below normal, levothyroxine 
(LT4) should be administered during pregnancy.  
In women with thyroid autoantibodies and serum TSH <2 mU/L, LT4 
treatment is not warranted; however, serum TSH and free FT4 should be 
measured later in gestation, preferably at the end of the second trimester. 
For women with thyroid autoantibodies and TSH between 2 and 4 mU/L in 
early gestation, treatment with LT4 should be considered. It is important to 
consider that serum TSH is downregulated during the first half of gestation 
by hCG.47 However, further studies are required to understand if all women 
with positive thyroid autoantibodies should be started on LT4 therapy 
during their pregnancies to decrease miscarriage rate. 
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AIM OF THE STUDY 
The aim of the study was to find out the association between Anti-
TPO antibody and recurrent miscarriages  
To evaluate obstetric complications such as Pre Eclampsia and 
Preterm labour in them 
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REVIEW OF LITERATURE 
1. L. Mehran,1 M. Tohidi, F. Sarvghadi, H. Delshad, A. Amouzegar,O. P. 
Soldin, and F. Azizi in a study of Management of Thyroid Peroxidase 
Antibody Euthyroid Women in Pregnancy: Comparison of the American 
Thyroid Association and the Endocrine Society Guidelines concluded that 
The current available data regarding associations between thyroid 
autoantibodies and spontaneous or recurrent pregnancy loss and preterm 
delivery is convincing. However, the reduction of these complications by 
treatment with LT4 supplementation is less robust. The evidence is not 
conclusive enough to recommend screening for thyroid autoantibodies or 
for the treatment of euthyroid women who are positive for thyroid 
autoantibodies during pregnancy. Both sets of guidelines discussed here are 
of high quality, and there does not seem to be contradiction or disagreement 
between the recommendations of the American Thyroid Association (2011) 
and of the Endocrine Society (2012) on the screening and management of 
women with thyroid autoantibodies in pregnancy. They suggested that 
either one of the two guidelines may be used by clinicians for appropriate 
and up-to-date management of thyroid autoimmunity during pregnancy. 
2. Alex Stagnaro-Green, MD; Sheila H. Roman, MD; Rhoda H. Cobin, MD; 
et al in a study of Detection of At-Risk Pregnancy by Means of Highly 
Sensitive Assays for Thyroid Autoantibodies screened 552 women who 
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presented to their obstetrician in the first trimester of pregnancy using 
highly sensitive enzyme-linked immunosorbent assays for the presence of 
thyroglobulin and thyroidperoxidase autoantibodies and found an incidence 
of positivity of 19.6%. The tendency to secrete detectable levels of thyroid 
autoantibodies was significantly correlated with an increased rate of 
miscarriage. Thyroid autoantibody—positive women miscarried at a rate of 
17%, compared with 8.4% for the autoantibody-negative women. Individual 
levels of thyroglobulin and thyroidperoxidase autoantibodies were similarly 
related to this increased miscarriage rate, with no evidence of autoantibody 
specificity in the relationship. Furthermore, the increase in miscarriages 
could not be explained by differences in thyroid hormone levels, the 
presence of cardiolipin autoantibodies, maternal age, gestational age at the 
time of maternal entry into the study, or previous obstetric history and 
concluded that thyroid autoantibodies are an independent marker of "at-
risk" pregnancy. 
3. MF Prummel and WM Wiersinga in a study of Thyroid autoimmunity and 
miscarriage in European Journal of Endocrinology with aim to ascertain 
the strength of the association between thyroid autoimmunity and 
miscarriage,  performed a meta-analysis of both case-control and 
longitudinal studies performed since 1990 when this association was first 
described. A clear association between the presence of thyroid antibodies 
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and miscarriage was found with an odds ratio (OR) of 2.73 (95 % 
confidence interval (CI), 2.20-3.40) in eight case-control and ten 
longitudinal (OR, 2.30; 95 % CI, 1.80-2.95) studies. This association may 
be explained by a heightened autoimmune state affecting the fetal allograft, 
of which thyroid antibodies are just a marker. Alternatively, the association 
can be partly explained by the slightly higher age of women with 
antibodies compared with those without (mean+/-S.D. age difference, 
0.7+/-1.0 years; P<0.001). A third possibility is mild thyroid failure, as 
thyroid-stimulating hormone (TSH) levels in antibody-positive but 
euthyroid women are higher than in antibody-negative women: difference 
0.81+/-0.58 mU/l (P=0.005). Randomized clinical trials with l-thyroxine 
(aiming at TSH values between 0.4 and 2.0 mU/l) and with selenium (to 
decrease antibodies against thyroid peroxidase) are clearly needed to 
elucidate further the nature of this association. 
4. Thyroid autoimmunity and the risk of miscarriage Alex Stagnaro-Green, 
Daniel Glinoer in a study Thyroid autoimmunity and the risk of miscarriage 
concluded that in approximately one-third of all pregnancies end in 
miscarriage. The etiology of recurrent abortion remains unknown in 
approximately 50% of all women. In the early 1990s it was discovered that 
unselected euthyroid women who present with thyroid antibodies (thyroid 
peroxidase and thyroglobulin) in the first trimester of pregnancy have a 
two–four-fold increase in their miscarriage rates. Although the etiology of 
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miscarriage in thyroid antibody women remains unknown, recent data have 
revealed a potential direct effect of thyroglobulin antibodies on pregnancy 
loss in a murine model. Uncontrolled studies assessing the effect of 
levothyroxine on decreasing the miscarriage rate in euthyroid antibody 
positive women, have demonstrated a decreased miscarriage rate. 
5. Kris Poppe, Brigitte Velkeniers& Daniel Glinoer in a study of The role of 
thyroid autoimmunity in fertility and pregnancy found that Hypothyroidism 
influences ovarian function by decreasing levels of sex-hormone-binding 
globulin and increasing the secretion of prolactin. In women of reproductive 
age, hypothyroidism can be reversed by thyroxine therapy to improve 
fertility and avoid the need for use of assisted reproduction technologies. 
For infertile women, preparation for medically assisted pregnancy 
comprises controlled ovarian hyperstimulation that substantially increase 
circulating estrogen concentrations, which in turn can severely impair 
thyroid function. In women without thyroid autoimmunity these changes are 
transient, but in those with thyroid autoimmunity estrogen stimulation might 
lead to abnormal thyroid function throughout the remaining pregnancy 
period. Prevalence of thyroid autoimmunity is significantly higher among 
infertile women than among fertile women, especially among those whose 
infertility is caused by endometriosis or ovarian dysfunction. Presence of 
thyroid autoimmunity does not interfere with normal embryo implantation, 
but the risk of early miscarriage is substantially raised. Subclinical and overt 
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forms of hypothyroidism are associated with increased risk of pregnancy-
related morbidity, for which thyroxine therapy can be beneficial. Systematic 
screening for thyroid disorders in pregnant women remains controversial 
but might be advantageous in women at high risk, particularly infertile 
women. 
6. Roberto Negro, Gianni Formoso, TizianaMangieri, Antonio Pezzarossa, 
DavideDazzi, Haslinda Hassan in a study of Levothyroxine Treatment in 
Euthyroid Pregnant Women with Autoimmune Thyroid Disease: Effects on 
Obstetrical Complications conducted in a total of 984 pregnant women; 
11.7% were thyroid peroxidase antibody positive (TPOAb+). The TPOAb+ 
patients were divided into two groups: group A (n = 57) was treated with 
LT4, and group B (n = 58) was not treated. The 869 TPOAb− patients 
(group C) served as a normal population control group. Rates of obstetrical 
complications in treated and untreated groups were measured. They found 
that, at baseline, TPOAb+ had higher TSH compared with TPOAb−; TSH 
remained higher in group B compared with groups A and C throughout 
gestation. Free T4 values were lower in group B than groups A and C after 
30 wk and after parturition. Groups A and C showed a similar miscarriage 
rate (3.5 and 2.4%, respectively), which was lower than group B (13.8%) [P 
< 0.05; relative risk (RR), 1.72; 95% confidence interval (CI), 1.13–2.25; 
and P < 0.01; RR = 4.95; 95% CI = 2.59–9.48, respectively]. Group B 
displayed a 22.4% rate of premature deliveries, which was higher than 
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group A (7%) (P < 0.05; RR = 1.66; 95% CI = 1.18–2.34) and group C 
(8.2%) (P < 0.01; RR = 12.18; 95% CI = 7.93–18.7). They concluded that 
the Euthyroid pregnant women who are positive for TPOAb develop 
impaired thyroid function, which is associated with an increased risk of 
miscarriage and premature deliveries. Substitutive treatment with LT4 is 
able to lower the chance of miscarriage and premature delivery. 
7.  R. Negro, G. Formoso, L. Coppola, G. Presicce, T. Mangieri, A. Pezzarossa, 
D. Dazzi in a study of Euthyroid women with autoimmune disease 
undergoing assisted reproduction technologies: The role of autoimmunity 
and thyroid function to assess if patients with autoimmune thyroid disease 
undergoing assisted reproduction technologies (ART) are afflicted by poor 
pregnancy and/or delivery rate and if the outcome is conditioned by pre-
ART thyroid status. The study was retrospective (from January 2000 to 
January 2005) and was carried out at the Division of Physiopathology of 
Human Reproduction. Women who underwent ART were tested for TSH, 
free T4 (FT4), thyroid peroxidase antibodies (TPOAb) before and during 
pregnancy. A total of 416 euthyroid women were selected; 42 (10.1%) were 
TPOAb (+). Women >35 yr were excluded. The endpoints were pregnancy 
and delivery rates. Results: no differences in pregnancy and delivery rates 
were observed between women with and without antibodies. In TPOAb (+), 
women who failed to become pregnant or miscarried displayed higher TSH 
values before ART (2.8 mlU/l) compared to the ones who delivered (1.6 
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mlU/l; p=0.032) and compared to TPOAb (−) (1.1 mlU/l; p=0.018). 
Conclusions: in euthyroid women undergoing ART the pregnancy and 
delivery rates are not affected by the presence of TPOAb. In TPOAb (+) 
high-normal TSH values are associated with increased risk of unsuccessful 
pregnancy or subsequent miscarriage. 
8. F.H. Rushworth, M. Backos, R. Rai I.T. Chilcott, N. Baxter L. Regan in a 
study of Prospective pregnancy outcome in untreated recurrent miscarriers 
with thyroid autoantibodies with a purpose to determine the prevalence of 
thyroid antibodies in women with recurrent miscarriage and to observe 
whether their presence was predictive of future pregnancy outcome. A total 
of 870 consecutive, non-pregnant women with a history of three or more 
pregnancy losses and normal parental karyotypes were investigated for the 
presence of thyroglobulin antibodies (TgAb) and for thyroid microsomal 
antibodies (TmAb). Thyroid antibodies were found in 162 (19%) women. 
TgAb only were found in eight women (5%); TmAb only in 98 (60%) and 
both TgAb and TmAb were found in 56 (35%). Thirteen women had a 
history of thyroid disease and a further 15 women were found to have 
abnormal thyroid function. All 28 were excluded from the pregnancy 
outcome study. Among the remaining 134 thyroid antibody positive 
women, 36 women were not tested and normal thyroid stimulating hormone 
results were obtained for 98. In the group proven euthyroid, 14 of 24 
untreated pregnancies resulted in live births (58%). Among the 710 thyroid 
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antibody negative women, 47 of 81 untreated pregnancies resulted in live 
births (58%). The future risk of pregnancy loss in women with unexplained 
recurrent miscarriage is not affected by their thyroid antibody status. 
9. Amir Iravani, Maryam Saeedi, JalilPakravesh, SepehrHamidi, 
MehrshadAbbasi in Thyroid Autoimmunity and Recurrent Spontaneous 
Abortion in Iran: A Case-Control Study with objective to determine the 
association of thyroglobulin antibodies (TG-Ab) and thyroid peroxidase 
antibodies (TPO-Ab) with recurrent spontaneous abortion in a euthyroid, 
nonpregnant population of women in Iran. This case-control study 
conducted between November 2003 and September 2006 in Tehran, Iran, 
nonpregnant women with a history of 3 or more consecutive pregnancy 
losses and age-matched, healthy parous women without a history of 
reproductive problems were assessed. Thyroid function tests were 
performed, which included assessment of thyroid-stimulating hormone, 
triiodothyronine, thyroxine, and the presence of TG-Ab and TPO-Ab. A 
total of 641 patients and 269 controls were included. Mean age (± SD) was 
30.6 ± 6.4 years (range, 16-51 years) in the patient group and 30.05 ± 6.6 
years (range, 18-48 years) in the control group. Thyroid antibodies were 
present in 157 of 641 patients (24.5%) and in 34 of 269 controls (12.6%) 
(P<.001). The presence of thyroid antibodies was significantly associated 
with recurrent abortion independent of the impact of age with an odds ratio 
of 2.24 (95% confidence interval, 1.5-3.35). They concluded that TG-Ab 
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and TPO-Ab were identified more frequently in women with recurrent 
abortions compared with controls, and thyroid autoimmunity was 
independently associated with a higher risk of recurrent abortion. 
10. ShakilaThangaratinam, Alex Tan, Ellen Knox, Mark D Kilby, 
ArriCoomarasamy in a study of Association between thyroid autoantibodies 
and miscarriage and preterm birth: meta-analysis of evidence with an 
objective to  evaluate the association between thyroid autoantibodies and 
miscarriage and preterm birth in women with normal thyroid function and 
to assess the effect of treatment with levothyroxine on pregnancy outcomes 
in this group of women. The study design was Systematic review and meta-
analysis. With Data sources Medline, Embase, Cochrane Library, and 
SCISEARCH (inception-2011) without any language restrictions. They 
used a combination of key words to generate two subsets of citations, one 
indexing thyroid autoantibodies and the other indexing the outcomes of 
miscarriage and preterm birth. The Study selection included Studies that 
evaluated the association between thyroid autoantibodies and pregnancy 
outcomes were selected in a two stage process. Two reviewers selected 
studies that met the predefined and explicit criteria regarding population, 
tests, and outcomes. Data synthesis Odds ratios from individual studies 
were pooled separately for cohort and case-control studies with the random 
effects model. 
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Results included 30 articles with 31 studies (19 cohort and 12 case-
control) involving 12 126 women assessed the association between thyroid 
autoantibodies and miscarriage. Five studies with 12 566 women evaluated 
the association with preterm birth. Of the 31 studies evaluating miscarriage, 
28 showed a positive association between thyroid autoantibodies and 
miscarriage. Meta-analysis of the cohort studies showed more than tripling 
in the odds of miscarriage with the presence of thyroid autoantibodies (odds 
ratio 3.90, 95% confidence interval 2.48 to 6.12; P<0.001). For case-control 
studies the odds ratio for miscarriage was 1.80, 1.25 to 2.60; P=0.002). 
There was a significant doubling in the odds of preterm birth with the 
presence of thyroid autoantibodies (2.07, 1.17 to 3.68; P=0.01). Two 
randomised studies evaluated the effect of treatment with levothyroxine on 
miscarriage. Both showed a fall in miscarriage rates, and meta-analysis 
showed a significant 52% relative risk reduction in miscarriages with 
levothyroxine (relative risk 0.48, 0.25 to 0.92; P=0.03). One study reported 
on the effect of levothyroxine on the rate of preterm birth, and noted a 69% 
relative risk reduction (0.31, 0.11 to 0.90). They concluded that the presence 
of maternal thyroid autoantibodies is strongly associated with miscarriage 
and preterm delivery. There is evidence that treatment with levothyroxine 
can attenuate the risks. 
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MATERIALS AND METHODS 
RESERCH DESIGN 
Case control observational study 
STUDY SETTING 
The study was conducted in the Institute of Social Obstetrics in madras 
medical college between March2017 to March 2018 . The Study approved 
by Ethical committee of the hospital 
INCLUSION CRITERIA  
Patients with history of recurrent miscarriages ( more than 3 in first 
trimester)presenting to antenatal clinic in Madras Medical College. 
EXCLUSION CRITERIA 
Those with  
      1.anatomical uterine defects 
      2.Overt hypothyroid 
     3.Anti phospholipid antibody syndrome 
     4. other auto immune disorders 
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SAMPLE SIZE  
100 
METHOD 
All patients provided written informed consent. 50 women who presented 
with history of recurrent miscarriage were taken as cases &50 mothers 
without such history were taken as controls.  
Those with anatomic uterine defects, overt hypothyroidism, 
antiphospholipids syndrome and other autoimmune diseases were excluded 
from cases. 
Under quality control and safety procedures for sample collection 10ml 
venous blood sample was collected in vaccutainertubes .Serum samples 
were sent for anti-TPO and TSH assay. Serum TSH levels were determined 
using Micro particle Enzyme Immunoassay (MEIA) kits. 
Normal reference range in pregnancy for TSH: 0.35-2.5µIU/ml (as per our 
hospital reference value), values >2.5 µIU/ml were considered high for 
pregnancy. Anti- TPO antibodies quantitative determination was done using 
CLIA (Chemiluminescemt Immunoassay) kits . TPO levels >34 iu/ml were 
considered abnormal and these women were considered TPO+VE. Cases\ 
were evaluated for obstetrics complications such as 
preeclampsia and preterm labour. 
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RESULTS AND DISCUSSION 
The collected data were analysed with IBM.SPSS statistics software 
23.0 Version.To describe about the data descriptive statistics frequency 
analysis, percentage analysis were used for categorical variables and the 
mean & S.D were used for continuous variables. To find the significant 
difference between the bivariate samples in Independent groups the 
Unpaired sample t-test was used. To find the significance in categorical data 
Chi-Square test was used similarly if the expected cell frequency is less than  
5 in 2×2 tables then the Fisher's Exact was used. In all the above statistical 
tools the probability value .05 is considered as significant level.  
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AGE: 
A total of 100 patients were recruited for the study. 50 patients were in 
control group and 50 patients were case group.  
The Age distribution among the patients.  
 
Majority of the study subjects in control group were in the age group of <25 
years (n=32, 51.0%) and in case group were in the age group of >=25 years 
(n=31, 62.0%).  
Below the age group of 25 years 51 patients were recruited of which 
19(38%) were in case group and 32 (64%) were in control group.  
Above the age group of 25 years 49 patients were recruited of which 31 
(62%) were in case group and 18 (36%). 
 Groups Total 
Cases Controls 
Age < 25 yrs Count 19 32 51 
% 38.0% 64.0% 51.0% 
>= 25 yrs Count 31 18 49 
% 62.0% 36.0% 49.0% 
P value Chi Square test 0.009 
The p value was 0.009 which is significant. The women with age more 
than 25 years are at a higher risk for abortions. The mean age
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OBSTETRIC CODE: 
  Groups Total 
Cases Controls 
Obst 
code 
MULTI Count 50 24 74 
% 100.0% 48.0% 74.0% 
PRIMI Count 0 26 26 
% 0.0% 52.0% 26.0% 
Total Count 50 50 100 
% 
within 
Groups 
100.0% 100.0% 100.0% 
 
In the control group of the 50 patients 24 (48%) were Multigravida and 26 
(52%).   
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ABORTION HISTORY 
  Groups Total 
Cases Controls 
ABORTIONS 0 Count 0 36 36 
% 0.0% 72.0% 36.0% 
1 Count 0 10 10 
% 0.0% 20.0% 10.0% 
2 Count 0 4 4 
% 0.0% 8.0% 4.0% 
3 Count 48 0 48 
% 96.0% 0.0% 48.0% 
4 Count 2 0 2 
% 4.0% 0.0% 2.0% 
Total Count 50 50 100 
% 
within 
Groups 
100.0% 100.0% 100.0% 
The P Value is 0.0005. The p Value is significant. Case population  history 
of abortions is found to be significant than control population.
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GESTATIONAL AGE AT THE TIME OF DELIVERY 
  Groups Total 
Cases Controls 
GA Upto 36+6 Count 4 0 4 
% 8.0% 0.0% 4.0% 
> 36 to 
37+6 
Count 8 0 8 
% 16.0% 0.0% 8.0% 
>37 + 
38+6 
Count 16 3 19 
% 32.0% 6.0% 19.0% 
>38 + 
39+6 
Count 16 14 30 
% 32.0% 28.0% 30.0% 
> 39 Count 6 33 39 
% 12.0% 66.0% 39.0% 
Total Count 50 50 100 
% 
within 
Groups 
100.0% 100.0% 100.0% 
 
In the case group 4 (8%) patients were in the preterm group.  
0.0005. Patients with recurrent spontaneous abortion have a significant 
chance of having preterm labour.  
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the p Value is 
> 39
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THE PLACE OF RESIDENCE 
  Groups Total 
Cases Controls 
RESIDENCE Rural Count 24 21 45 
% 48.0% 42.0% 45.0% 
Urban Count 26 29 55 
% 52.0% 58.0% 55.0% 
Total Count 50 50 100 
% 
within 
Groups 
100.0% 100.0% 100.0% 
 
Of the Total 100 patients in the study 45 patients were from the rural 
population and 55 patients were in urban population. This shows that the 
place of residence is insignificant with recurrent spontaneous miscarriage.
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SOCIO ECONOMIC STATUS 
  Groups Total 
Cases Controls 
socio 
economic 
status 
LM Count 13 17 30 
% 26.0% 34.0% 30.0% 
UL Count 27 21 48 
% 54.0% 42.0% 48.0% 
UM Count 10 12 22 
% 20.0% 24.0% 22.0% 
Total Count 50 50 100 
% within 
Groups 
100.0% 100.0% 100.0% 
Out of 100 patients 30% were in low middle
lowerclass , 22 % in upper middle class . Thus, socio economic status found 
be insignificant in recurrent spontaneous miscarriage.
Bar diagram showing Socio economic status
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 was 58%.  
 60%. 
60.0%
58 
 
URINE ALBUMIN 
  Groups Total 
Cases Controls 
urine 
albumin 
1+ Count 2 0 2 
% 4.0% 0.0% 2.0% 
2+ Count 2 0 2 
% 4.0% 0.0% 2.0% 
3+ Count 2 0 2 
% 4.0% 0.0% 2.0% 
Nil Count 44 50 94 
% 88.0% 100.0% 94.0% 
Total Count 50 50 100 
% 
within 
Groups 
100.0% 100.0% 100.0% 
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Urine albumin was found to be more than 1+ in 12% in case group. among 
the case group 4% were urine albumin 1+, 4 % were 2+, 4% were 3 +. 
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MATERNAL RISK FACTORS 
  
Groups 
Total Cases Controls 
COMORBIDIT
IES 
Nil Coun
t 
47 50 97 
% 94.0
% 
100.0
% 
97.0
% 
Obesi
ty 
Coun
t 
3 0 3 
% 6.0% 0.0% 3.0% 
Total Coun
t 
50 50 100 
% 
withi
n 
Grou
ps 
100.0
% 
100.0
% 
100.0
% 
 
 
In case group only 6% of the population. (Obese 
statistically insignificant with recurrent spontaneous miscarriage.
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MATERNAL COMPLICATIONS: 
  
Groups 
Total Cases Controls 
Maternal 
complicati
on 
No 
complicati
ons 
Coun
t 
40 50 90 
% 80.0
% 
100.0
% 
90.0
% 
Preeclamps
ia 
Coun
t 
6 0 6 
% 12.0
% 
0.0% 6.0% 
Preterm 
labour 
Coun
t 
3 0 3 
% 6.0% 0.0% 3.0% 
PROM Coun
t 
1 0 1 
% 2.0% 0.0% 1.0% 
Total Coun
t 
50 50 100 
% 
withi
n 
Grou
ps 
100.0
% 
100.0
% 
100.0
% 
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Preeclampsia was noted among 12% of mothers of with recurrent 
spontaneous miscarriages,. Preterm labour was noted in 6% of the case 
population and Preterm rupture of membranes was seen in 2% of the case 
population. The p value was 0.011. which is significant. The incidence of 
complication among women with recurrent spontaneous miscarriage is 
higher than the general population.  
 
 
  
80.0%
100.0%
12.0%
6.0% 2.0%
0.0%
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Maternal complication
No complications Preeclampsia Preterm labour PROM
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  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 11.111a 3 .011 
Likelihood Ratio 14.976 3 .002 
N of Valid Cases 100     
 
 
  
Pre -term labour  
 
Out of 50 patients in RSM group 4(8%) developed preterm labour.
  
TERM preterm 
term 
Total 
 
8.0%
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
120.0%
 
Groups 
Cases Controls
Count 4 0 
% 8.0% 0.0% 
Count 46 50 
% 92.0% 100.0%
Count 50 50 
% 
within 
Groups 
100.0% 100.0%
0.0%
92.0%
100.0%
Cases Controls
Term
Preterm Term
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Total 
 
4 
4.0% 
96 
 96.0% 
100 
 100.0% 
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TSH 
  
Groups 
Total Cases Controls 
TSH Normal Count 46 50 96 
% 92.0% 100.0% 96.0% 
Sub clinical 
hypothyroid 
Count 4 0 4 
% 8.0% 0.0% 4.0% 
Total Count 50 50 100 
% 
within 
Groups 
100.0% 100.0% 100.0% 
 
OUT of 50 cases 4 (8%) of recurrent spontaneous miscarriages were found 
to be subclinical hypothyroid. TSH was found to normal in 46(92%)of 
RSM.  
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ANTI TPO POSITIVITY: 
 
Out of 50 patients in case group 14 (28%) were ANTI TPO positive  and 36 
(72%) were ANTI TPO negative.  
Out of 50 patients in control group, 3(6%)were ANTI TPO POSITIVE and 
47(94%)were ANTI TPO negative. P value 0.006 shows that ANTI TPO 
POSITIVITY were significant in RSM group. 
 
 
 Groups Total 
Cases Controls 
ANTI TPO 
POSITIVE 
Negative Count 36 47 83 
% 72.0% 94.0% 83.0% 
Positive Count 14 3 17 
% 28.0% 6.0% 17.0% 
Total Count 50 50 100 
% 
within 
Groups 
100.0% 100.0% 100.0% 
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Value df 
Asymp. 
Sig. 
(2-sided) 
Exact 
Sig. 
(2-sided) 
Exact 
Sig. 
(1-sided) 
Pearson 
Chi-Square 
8.575a 1 .003     
Continuity 
Correctionb 
7.087 1 .008     
Likelihood 
Ratio 
9.185 1 .002     
Fisher's 
Exact Test 
      .006 .003 
N of Valid 
Cases 
100         
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GROUP STATISTICS: 
Groups N Mean Std. 
Deviation 
Std. 
Error 
Mean 
AGE Cases 50 25.92 2.702 .382 
Controls 50 24.18 1.380 .195 
HEIGHT Cases 50 158.50 5.100 .721 
Controls 50 158.72 6.075 .859 
WEIGHT Cases 50 69.06 8.594 1.215 
Controls 50 68.34 4.856 .687 
SBP Cases 50 113.80 14.576 2.061 
Controls 50 106.60 6.581 .931 
DBP Cases 50 72.10 11.819 1.671 
Controls 50 71.40 6.392 .904 
BIRTH 
WEIGHT 
Cases 50 2.917 .3599 .0509 
Controls 50 2.982 .3022 .0427 
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SUMMARY 
The study population consisted of apparently healthy pregnant 
women with a history of unexplained recurrent miscarriage during the first 
trimester (5 – 13 weeks of gestation). Depending on the increased necessity 
of the thyroid gland for normal development, growth and metabolic 
homeostasis during in pregnancy and fetal life, changes associated with 
pregnancy require an increased availability of thyroid hormones by 40% to 
100% in order to meet the needs of mother and fetus during pregnancy. 
 The relation of the thyroid antibodies with miscarriage is an 
important issue that has attracted the interest of many investigators. A 
number of researches have been published concerning the relation of 
thyroid autoimmunity and miscarriage which include healthy women, 
women with recurrent miscarriage and those undergoing assisted 
reproductive techniques. All these studies are not easily comparable due to 
the different selection criteria employed for specific aims for each study, but 
most studies have shown a significant positive association between the 
presence of thyroid autoantibodies and miscarriage rate. 
 It was suggested that those autoantibodies, which can also be higher 
in the euthyroid patients, may produce a threat for miscarriage in the 
subsequent pregnancy. Thyroid peroxidase antibodies target the thyroid 
peroxidase enzyme that assists in the production and metabolism of thyroid 
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hormone. Although they are widely seen in autoimmune thyroid disorders, 
thyroid peroxidase antibodies are not necessarily a sign of disease. In up to 
26 percent of healthy women, low levels of TPO antibodies are seen. In our 
study the control group the TPO was positive in among 6 percent of the 
study population.  
In the normal healthy population, when TPO antibodies are 
accompanied by a higher TSH level (> 2.0 mu/L); they suggest an increased 
risk for developing Hashimoto’s thyroiditis. In spite of many studies 
available regarding the physiological changes in the thyroid function during 
pregnancy, it is uncertain if functional disorders of the thyroid gland play a 
role in the aetiology of spontaneous miscarriages. However, this  study was 
about evaluating the thyroid peroxidase antibody in recurrent spontaneous 
miscarriage, risk factors and the obstretric complication in the study 
population.  
In our study showed the mean age of was 25.92 in case population 
and in control population was 24.18. In our that significant correlation the 
age of the women and the incidence recurrent spontaneous miscarriages. 
The mean height was 158.5 cm in cases and 158.72 cm in controls. 
The weight 69.06 kg in cases and 68.34 kg in control group. The was  no 
significance about the of height and weight of the women with recurrent 
spontaneous miscarriage   
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The residence of the women has no significance with recurrent 
spontaneous miscarriage.  In our study the case population resided in urban 
was 52% and in rural 48% and in the control population the urban was 58% 
and rural population was 42%. 
There was no  significance with socioecomic status of the women. 
In the case group 12 (6) percentage developed preeclampsia.  Among 
these 6 women 2 women had severe preeclampsia. These 2 women 
developed severe preeclampsia at 37 weeks of gestation and  pregnancy was 
terminated.  Urine albumin was 3+ in 2 women. Urine albumin was 1+ and 
2 + was seen in  4 women. Among the 6 women who developed 
preeclampsia 4 patients were ANTI TPO positive. 
Three women developed preterm labour. One women at 35Weeks and 
other two at 36  all three women had vaginal delivery  and babies had good 
apgar.  Among these 3 women who had preterm labour 2 patients had ANTI 
TPO positive after ruling out other causes of Pre term labour. 
Among case population one women developed PREMATURE 
RUPTURE OF at MEMBRANES AT 38 weeks and delivered by caesarean 
delivery with good apgar and the women was ANTI TPO POSITIVE. 
In our study the incidence of subclinical hypothyriods was 4%.The 
ANTI TPO positive in a total of 17, patients  in the case population 14  
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patient were anti TPO positive and 3patients were ANTI TPO positive in 
the control population. The p value was 0.006. The TPO positivity is 
significant in the recurrent spontaneous miscarriage.  
In our study the prevalence of TPO positivity was higher in women 
with history of RSM than those with uneventful pregnancy history. Again 
those with TPO positive have higher prevalence of subclinical 
hypothyroidism. 
Thyroid hormones are essential for the developing fetus. Hence a 
pregnant woman needs thyroxine more than non-pregnant lady to provide 
T4 to both herself and her developing fetus. The fetus's thyroid gland is not 
fully functional until after 12 weeks of pregnancy. If the mother does not 
have sufficient thyroid hormones, she may be at increased risk of 
miscarriage. Since the majority of women are not sure that they are pregnant 
until four to six weeks after the last menstrual period, they do not go to see 
doctors and test their thyroid function until the first trimester is more than 
half over.  
It is advisable to suggest thyroid investigation to the pregnant women 
with history of recurrent miscarriage as soon as possible after knowing they 
are pregnant. Management of thyroid diseases during pregnancy requires 
special considerations because pregnancy induces major changes in thyroid 
function, and maternal thyroid disease can have adverse effects on the 
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pregnancy and the fetus. Care requires coordination among several 
healthcare professionals. 
Avoiding maternal and fetal thyroid dysfunction is of major 
importance because of potential damage to fetal neural development, an 
increased incidence of miscarriage, and preterm delivery. 
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CONCLUSION 
Thyroid autoimmunity and subclinical hypothyroid can be considered 
as risk marker for recurrent spontaneous miscarriage.  Euthyroid women in 
early stage of pregnancy with TPO antibody positive are still at risk of 
developing hypothyroidism later. There serum TSH level needs to 
monitored.  
The TSH levels were found to be normal in miscarriage women 
compared with healthy pregnant women. The feedback mechanism of 
thyroid-pituitary glands is profound or not properly works in recurrent 
miscarriage women. 
The thyroid antibodies can only affect pregnant women when their serum 
TSH level is relatively within the actual normal range.  
 The total thyroid hormones (TT4 and TT3) as well as decreased in 
recurrent miscarriage women compared to the control subjects. 
 Most of women with recurrent miscarriage were euthyroid 
In patients with recurrent miscarriage and if all the other work up for 
recurrent pregnancy loss have turned out to be negative  then tests for 
detecting anti TPO should be considered even with normal TSH levels. And 
if anti TPO antibodies turns out to be positive, treatment with Tablet 
levothyroxine can be considered. 
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ANNEXURES: 
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PROFORMA 
Name:     Educational status: 
Age: 
Residence: 
Socio economic status: 
LMP:   
DEE: 
GA: 
Obstetric history; 
1st:     
2nd:     
3rd:   
4th : 
Present history: 
h/o labour pain  
h/o draining pv 
h/o bleeding pv 
h/o imminent symptoms 
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Past history: 
Diabetes: Yes ( ) No ( ) 
Hypertension: Yes ( ) No ( ) 
Renal disease: Yes ( ) No ( ) 
Thyroid disorder: Yes ( )Hyper ( ) Hypo ( ). Other ( ) No ( ) 
Congenital abnormality: Yes ( ) No ( ) 
APLA positivity: Yes ( ) No ( ) 
 
Clinical examination: 
Height      General condition: 
Weight:     Pallor: 
BMI:      Pedal edema: 
Temperature:    Icterus: 
BP: 
PR: 
RR: 
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Systemic examination: 
CVS: 
RS: 
Per abdomen: 
Per speculum: 
Per Vaginal: 
Investigations 
Urine albumin 
TSH 
FT3 
FT4 
ANTI TPO 
Other routine investigations: 
Maternal complication 
MODE OF DELIVERY  
LN ( )    C- SECTION ( ) 
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FOETAL OUTCOME  
Alive/ 
Term/ preterm 
Boy/girl 
Apgar 
Birth weight 
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INFORMATION SHEET 
We are conducting a study on “ANTI-THYROID PEROXIDASE  
POSITIVITY IN RECURRENT MISCARRIAGE AND ASSOCIATED 
OBSTERICS COMPLICATIONS” among the patients in Institute of 
Obstetrics and Gynaecology, Madras Medical College, Chennai and for that 
your clinical details may be valuable to us. 
We are selecting certain patients and if you are found eligible, we may be 
using your clinical details in such a way so as to not affect your final report or 
management. 
The privacy of the patient in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in the study is voluntary. You are free to decide whether to 
participate in the study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The result of the special study may be intimated to you at the end of the 
study period or during the study. If anything is found abnormal, which may aid 
in management or treatment. 
Signature of Investigator:    Signature of Participant: 
Date : 
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ேநாயாள தகவ தா 
 
ம ம க	சிைத ஏபதலி எதி 
ைதரா ெபராஸிேட  பாசி!"வ$!" ம% அத' 
ெதாடைடய மகேபறிய சிகக* 
 
 
 
ேநாயாள-க.கான தகவ : 
  உ2கைள இ4த ஆரா	சிய$ ப26 ெகா*ள 
அைழகிேறா. நா2க* உ2க.6 ெகா6 இ4த 
ப"வ9தி உ*ள வ$வர2கைள ெகா ந:2க* இ4த 
ஆரா	சி6 உ!படலாமா அல; நிராக<கலாமா 
எ'பைத ந:2கேள =" ெசயலா. ேம> உ2கள-' 
ச4ேதக2கைள? எ2கள-ட ேக!கலா. ந:2க* எ2க* 
ஆரா	சி6 த6தி உ*ளவரா6 ப!ச9தி, ெச'ைன 
ம9;வ க@<ய$நைடெப% இ4த ஆரா	சிய$ 
உ2கைள ப2ெக9;ெகா*ள ெசேவா. 
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CONSENT FORM 
“ANTI-THYROID PEROXIDASE  POSITIVITY IN RECURRENT 
MISCARRIAGE AND ASSOCIATED OBSTERICS COMPLICATIONS” 
  
STUDY CENTRE : 
Institute of Obstetrics and Gynaecology,  
Madras Medical College, Chennai 
 
PARTICIANT NAME:       AGE: 
 MRD No.: 
   
I confirm that I have understood the purpose of the procedure for the 
above study. I have an opportunity to ask the question and all my questions and 
doubts have been answered to my satisfaction. 
   
I have been explained about the possible complication that may occur 
during the procedure. I understand that my participation in the study in 
voluntary and that I am free to withdraw at any time without giving any reason. 
   
I understand that investigator, regulatory authorities and the Ethics 
Committee will not need my permission to look at my health records both in the 
respective current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. I understand that my identity 
will not be revealed in any information released to third parties of published, 
unless as required under the law. I agree not to restrict the use of any or results 
that arise from the study.  
I hereby consent to participate in the study of “ANTI-THYROID 
PEROXIDASE  POSITIVITY IN RECURRENTMISCARRIAGE AND 
ASSOCIATED OBSTERICS COMPLICATIONS” 
SIGNATURE OF THE PARTICIPANT:      
DATE  : 
PLACE: 
 
NAME OF THE INVESTIGATOR:        
INSTITUTION: 
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ய ஒத பவ 
 
ம ம க	சிைத ஏபதலி எதி 
ைதரா ெபராஸிேட  ஆ'"பா" பாசி!" வ$!" 
ம% அத' ெதாடைடய மகேபறிய சிகக* 
ஆ நட9தப இட: ெச'ைன ம9;வ க@<, 
ெச'ைன. 
 
ப26ெப%பவ<' ெபய :                
ப26ெப%பவ<' வய; : 
 
ப26ெப%பவ<' எ : 
 
 இ4த ஆவ$ 6றிப$!*ள ம9;வ ஆவ$' 
வ$வர2க* என6 வ$ளகப!ட;. நா' இAவாவ$ 
த'ன-	ைசயாக ப2ேககிேற'. எ4த காரண9தினா> 
எ4த ச!ட சிக>6 உ!படாம நா' இAவாவ$ 
இ4; வ$லகிெகா*ளலா எ'% அறி4; 
ெகாேட'. 
 இ4த ஆ சப4தமாகேவா அைத சா4த ேம> 
ஆ ேமெகா*.ேபா; இ4த ஆவ$ ப26 
ெப% ம9;வ எ'Cைடய ம9;வ அறிைகைய 
பாபத6 எ' அCமதி ேதைவய$ைல எ'பைத 
அறி4; ெகா*கிேற'. இ4த ஆவ$' Dல கிைட6 
="ைவ பய'ப9திெகா*ள ம%கமா!ேட'. 
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 இ4த ஆவ$ ப26ெகா*ள ஒெகா*கிேற'. 
இ4த ஆைவ ேமெகா*. ம9;வ அண$6 
உைம?ட' இேப' எ'% உ%தியள-கிேற'. 
 
 
ப2ேகபவ<' ைகெயாப சா!சிகள-' ைகெயாப 
 
 
இட :       இட : 
 
ேததி :       ேததி : 
 
ப2ேகபவ<' ெபய ம% வ$லாச : 
 
 
 
 
 
 
 
ஆவாள<' ைகெயாப 
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